RxDoctor Payments DataLook up a doctor →

Kirsten Siwy, PA

Medical · Leland, NCNPI 1003559832

Payments from drug & device makers

$12,595in general payments, 2019–2025

Across 560 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • UCB, Inc.$1K
  • AstraZeneca$1K
  • Novartis$894
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$12,48799%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,595 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$430,844
Medicare patients
593
Services billed
34,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib43$267,972
Humira(Cf) PenAdalimumab24$225,685
Enbrel SureclickEtanercept16$112,250
TymlosAbaloparatide25$78,429
ForteoTeriparatide12$51,840
Teriparatide12$42,732
MethotrexateMethotrexate Sodium166$3,453
Hydroxychloroquine Sulfate75$3,194
Celecoxib68$1,797
Leflunomide11$1,215
Prednisone291$1,209
Diclofenac Sodium104$1,140
Gabapentin100$970
Colchicine17$719
Duloxetine Hcl43$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,020$267,97243 claims
Radius Health, Inc.Tymlos$240$78,42925 claims
Lilly USA, LLCForteo$539$51,84012 claims
Scilex Pharmaceuticals Inc.Colchicine$26$71917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Leland

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →